Movement Alert｜Akeso Rises 3.32% in Regular Trading, Innovative Drug Payment Reform Continues to Catalyze Amid Sector-Wide Strength

Market Focus07-06

On July 6, Akeso (09926.HK) rose 3.32% in regular trading, trading at HK$103.7/share, with turnover of HK$229 million.

On the news front, the innovative drug payment reform continues to drive the biotech sector higher. All five of Akeso's self-developed new drugs across all approved indications have been included in the national medical insurance catalog, while its new drug Qiyoukang has completed its first batch of nationwide shipments, expected to accelerate commercial uptake. Additionally, the national medical insurance authority recently announced 557 drugs passing the initial review for medical insurance catalog inclusion and 54 drugs passing the commercial insurance innovative drug catalog review, marking the substantive advancement of the dual-catalog negotiation mechanism alongside new supportive policies including pre-application mechanisms and 8-year price protection.

Within the Biotechnology sector, peers showed broad-based gains: Remegen up 3.59%, Innovent Bio up 2.79%, 3SBio up 2.61%, SKB Bio up 2.2%, and BeiGene up 0.66%, reflecting continued industry beta resonance.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1177072380?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-06 09:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177072380","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Akeso Rises 3.32% in Regular Trading, Innovative Drug Payment Reform Continues to Catalyze Amid Sector-Wide Strength","media":"Market Focus","content":"<p><p>On July 6, Akeso (09926.HK) rose 3.32% in regular trading, trading at HK$103.7/share, with turnover of HK$229 million.</p><p>On the news front, the innovative drug payment reform continues to drive the biotech sector higher. All five of Akeso's self-developed new drugs across all approved indications have been included in the national medical insurance catalog, while its new drug Qiyoukang has completed its first batch of nationwide shipments, expected to accelerate commercial uptake. Additionally, the national medical insurance authority recently announced 557 drugs passing the initial review for medical insurance catalog inclusion and 54 drugs passing the commercial insurance innovative drug catalog review, marking the substantive advancement of the dual-catalog negotiation mechanism alongside new supportive policies including pre-application mechanisms and 8-year price protection.</p><p>Within the Biotechnology sector, peers showed broad-based gains: Remegen up 3.59%, Innovent Bio up 2.79%, 3SBio up 2.61%, SKB Bio up 2.2%, and BeiGene up 0.66%, reflecting continued industry beta resonance.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Akeso Rises 3.32% in Regular Trading, Innovative Drug Payment Reform Continues to Catalyze Amid Sector-Wide Strength</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Akeso Rises 3.32% in Regular Trading, Innovative Drug Payment Reform Continues to Catalyze Amid Sector-Wide Strength\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-06 09:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 6, Akeso (09926.HK) rose 3.32% in regular trading, trading at HK$103.7/share, with turnover of HK$229 million.</p><p>On the news front, the innovative drug payment reform continues to drive the biotech sector higher. All five of Akeso's self-developed new drugs across all approved indications have been included in the national medical insurance catalog, while its new drug Qiyoukang has completed its first batch of nationwide shipments, expected to accelerate commercial uptake. Additionally, the national medical insurance authority recently announced 557 drugs passing the initial review for medical insurance catalog inclusion and 54 drugs passing the commercial insurance innovative drug catalog review, marking the substantive advancement of the dual-catalog negotiation mechanism alongside new supportive policies including pre-application mechanisms and 8-year price protection.</p><p>Within the Biotechnology sector, peers showed broad-based gains: Remegen up 3.59%, Innovent Bio up 2.79%, 3SBio up 2.61%, SKB Bio up 2.2%, and BeiGene up 0.66%, reflecting continued industry beta resonance.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1177072380","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177072380","pubTimestamp":1783301971,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 6, Akeso (09926.HK) rose 3.32% in regular trading, trading at HK$103.7/share, with turnover of HK$229 million.On the news front, the innovative drug payment reform continues to drive the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"动感快讯|康方生物常规盘涨3.32%全板块走强下创新药支付改革持续催化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"On July 6, Akeso (09926.HK) rose 3.32% in regular trading, trading at HK$103.7/share, with turnover of HK$229 million.On the news front, the innovative drug payment reform continues to drive the biotech sector higher. All five of Akeso's self-developed new drugs across all approved indications have been included in the national medical insurance catalog, while its new drug Qiyoukang has completed its first batch of nationwide shipments, expected to accelerate commercial uptake. Additionally, the national medical insurance authority recently announced 557 drugs passing the initial review for medical insurance catalog inclusion and 54 drugs passing the commercial insurance innovative drug catalog review, marking the substantive advancement of the dual-catalog negotiation mechanism alongside new supportive policies including pre-application mechanisms and 8-year price protection.Within the Biotechnology sector, peers showed broad-based gains: Remegen up 3.59%, Innovent Bio up 2.79%, 3SBio up 2.61%, SKB Bio up 2.2%, and BeiGene up 0.66%, reflecting continued industry beta resonance.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1177072380","isCrawlerRequest":true}